Percutaneous fine-needle 5% ethanol-cisplatin intratumoral injection combined with second-line chemotherapy improves on the standard of care in patients with platinum- pretreated stage IV non-small cell lung cancer

Translational Oncology

Volumn 7, Issue 2, 2014, Pages 303-308

  Niu, Qi ^a   Wang, Wei ^a   Li, Qian ^b   Li, Yong ^a   Ruden, Douglas M ^c   He, Baoming ^a  

^a General Hospital of the People's Liberation Army   (China)

^b BEIJING LANGUAGE AND CULTURE UNIVERSITY   (China)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; FOLIC ACID; PACLITAXEL; PEMETREXED; PLATINUM;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COUGHING; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEMOPTYSIS; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEEDLE; OVERALL SURVIVAL; PNEUMOTHORAX; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; TREATMENT RESPONSE;

EID: 84902439164     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.02.017     Document Type: Article

References (19)

1. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, and Muller T, et al (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22, 1589-1597.
2. Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, Brose MS, Ellis LM, Erba H, and George DJ, et al (2013). Clinical cancer advances 2012: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 31, 131-161.
3. Niu Q, Wang W, Li Y, Ruden DM, Wang F, Li Y, Wang F, Song J, and Zheng K (2012). Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation. PLoS One 7, e41035 [Epub 2012 Jul 23].
4. Dean M, Fojo T, and Bates S (2005). Tumour stem cells and drug resistance. Nat Rev Cancer 5, 275-284.
5. Murphy M and Stordal B (2011). Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Drug Resist Updat 14, 177-190. http://dx.doi.org/10.1016/j.drup.2011.02.004 [Epub 2011 Mar 24].
6. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, and Provencio M, et al (2009). Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361, 958-967.
7. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, and Lowe ES, et al (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372, 1809-1818.
8. Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, and Gonzalez EE (2012). Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 13, 300-308.
9. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, and Bryson P (2007). Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 14, 195-208.
10. Niu Q, Wang W, Li Y, Ruden DM, Li Q, and Wang F (2013). Cisplatin in 5% ethanol eradicates cisplatin-resistant lung tumor by killing lung cancer side population cells and non-SP cells. Front Genet 4, 163. http://dx.doi.org/10.3389/fgene.2013.00163.
11. Niu Q, Wang W, Li Y, Qin S, Wang Y, Wan G, Guan J, and Zhu W (2011). Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol 11, 449-456.
12. Hamstra DA, Moffat BA, Hall DE, Young JM, Desmond TJ, Carter J, Pietronigro D, Frey KA, Rehemtulla A, and Ross BD (2005). Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor -a pharmacokinetic study. J Neurooncol 73, 225-238.
13. Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, and Siddik ZH (2012). Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol 30, 3345-3352.
14. Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, and Smith P, et al (2013). Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14, 38-47. http://dx.doi.org/10.1016/S1470-2045(12)70489-8.
15. Pietronigro D, Drnovsky F, Cravioto H, and Ransohoff J (2003). DTI-015 produces cures in T9 gliosarcoma. Neoplasia 5, 17-22.
16. Hassenbusch SJ, Nardone EM, Levin VA, Leeds N, and Pietronigro D (2003). Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial. Neoplasia 5, 9-16.
17. Jenkinson MD, Smith TS, Haylock B, Husband D, Shenoy A, Vinjamuri S, Walker C, Pietronigro D, and Warnke PC (2010). Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma. J Neurooncol 99, 103-113.
18. Tan W, Bailey AP, Shparago M, Busby B, Covington J, Johnson JW, Young E, and Gu JW (2007). Chronic alcohol consumption stimulates VEGF expression, tumor angiogenesis and progression of melanoma in mice. Cancer Biol Ther 6, 1211-1217.
19. Yamauchi Y, Izumi Y, Hashimoto K, Yashiro H, Inoue M, Nakatsuka S, Goto T, Anraku M, Ohtsuka T, and Kohno M, et al (2012). Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer. PLoS One 7, e33223 [Epub 2012 Mar 8].